ArticleCureus2025
Vonoprazan Therapy in Gastroesophageal Reflux Disease (GERD): Effects on the Severity and Frequency of GERD in Relation to Hiatus Hernia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to assess vonoprazan's effectiveness in reducing the severity and frequency of gastroesophageal reflux disease (GERD) symptoms in relation to hiatus hernia. Methods This prospective single-arm cohort study (before and after treatment) was conducted at Hayatabad Medical Complex, Peshawar, from January 1, 2025, to August 31, 2025. It enrolled 110 patients with GERD, based on clinical evaluation and endoscopic confirmation to exclude other pathologies and evaluate for the presence of hiatus hernia. Inclusion criteria included patients aged 18-65 years presenting with typical GERD symptoms, such as heartburn or regurgitation. Patients were excluded if they had a history of gastrointestinal surgery, esophageal malignancy, pregnancy, lactation, and significant hepatic or renal impairment or were on concurrent acid-suppressive medications. All patients were given 20 mg vonoprazan monotherapy for four weeks. Symptom severity and frequency were assessed pre- and post-treatment using a validated structured questionnaire. Clinical response evaluation and subgroup analysis were performed to evaluate treatment outcomes in patients with and without hiatus hernia. Results The total number of patients was 110, with a mean age of 43.65 ± 9.90 years and a mean BMI of 26.81 ± 2.76. Before treatment, 33 (30.0%) had severe symptoms, and 58 (52.7%) reported symptoms more than four times per week. Following treatment, 97 (88.2%) reported complete symptom resolution, and symptom frequency decreased significantly. Among the 32 (29.1%) with hiatus hernia, 20 (62.5%) became symptom-free. Analysis showed a significant reduction in both symptom severity and frequency (p < 0.001). Conclusion Vonoprazan improved the severity and frequency of GERD symptoms significantly, with better outcomes in patients without a hiatus hernia. It offers an effective alternative in GERD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.